한스바이오메드

042520KOSDAQ

43.0 / 100

Reference Date: 2026-10-23

Financial Score12.5 / 40

News Sentiment12.5 / 25

Momentum8.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Slightly down 4.1% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

HansBioMed, established in 1999, develops, manufactures, and sells skin and bone tissue implants and medical devices. Its key products, Bella Cell HD and SureFuse, account for approximately 61% of sales, with global expansion through overseas subsidiaries in the U.S., Thailand, and the U.K. The company continues to invest in R&D for regenerative medicine and new medical technologies.

Number of Employees

289people

Average Salary

41.5M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

7.63Industry Average 1.200.0Point

6.4x industry avg (risky)

ROE

-63.51Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

33.90Industry Average 100.006.5Point

Half of industry avg (excellent)

Trend 2023~20252.0 / 10 points

Revenue Growth Rate

2.0 / 3

Avg ▲7.3% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼2061.7% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -42.1% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (2%, downtrend)

Current 18,140Won52-week high 55,70052-week low 17,010

1-month return2.0Point

1m -4.07% (slight drop)

Volume trend5.0Point

Volume flat

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0

Neutral주식등의대량보유상황보고서(약식)2026-10-02